1.Arif MSA. Antibiotic resistant pattern of E. coli and Klebsiella species in Pakistan: Brief overview. J Microb Biochem Tech. 2017;9:6.
2.Kibret M, Abera B. Antimicrobial susceptibility patterns of E. coli from clinical sources in northeast Ethiopia. Afr Health Sci. 2011;11 Suppl 1:S40–45.
3.Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev.1998;11:589–603.
4.Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health. 2013;10:6235–54.
5.Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.
6.Talbot GH, Bradley J, Edwards JE, Jr., Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657–68.
7.Raut S GS, Adhikari B. Prevalence of extended spectrum beta-lactamases among E. coli and Klebsiella spp isolates in Manipal, Teaching Hospital, Pokhara, Nepal. JMID. 2015;5(2): 69–75.
8.Yusuf I, Haruna M, Yahaya H. Prevalence and antibiotic susceptibility of AmpC and ESBL producing clinical isolates at a tertiary health care center in Kano, North west Nigeria. Afr J Clin Exper Microbiol.2013;14: 109–19.
9.Bush K, Bradford PA. Beta-Lactams and beta-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med.2016;6(8).
10.Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2010;35:316–21.
11.Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–86.
12.Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect.2009;73:345–54.
13.Chaudhary U, Aggarwal R. Extended spectrum -lactamases (ESBL) - an emerging threat to clinical therapeutics. Indian J Med Microbiol.2004;22:75–80.
14.Bakshi P, Walia G, S J. Prevalence of extended spectrum β- lactamase in multidrug- resistant strains of gram negative bacilli. J Acad Indus Res.2013;1:558–60.
15.Upadhyay A, Parajuli P. Extended spectrum β-lactamases (ESBL)-producing Klebsiella species isolated at National Medical College and Teaching Hospital Nepal. Asian J Pharma and Clin Res. 2013;1:161–64.
16.Thenmozhi S, Moorthy K, Sureshkumar B, Suresh M. Antibiotic resistance mechanism of ESBL producing enterobacteriaceae in clinical field: A review. Int Pure App Biosci.2014;2:207–26.
17.Neupane S, Pant ND, Khatiwada S, Chaudhary R, Banjara MR. Correlation between biofilm formation and resistance toward different commonly used antibiotics along with extended spectrum beta lactamase production in uropathogenic Escherichia coli isolated from the patients suspected of urinary tract infections visiting Shree Birendra Hospital, Chhauni, Kathmandu, Nepal. Antimicrob Resist Infect Control.2016;5:5.
18.Nepal K, Pant ND, Neupane B, Belbase A, Baidhya R, Shrestha RK, Lekhak B, Bhatta DR, Jha B. Extended spectrum beta-lactamase and metallo beta-lactamase production among Escherichia coli and Klebsiella pneumoniae isolated from different clinical samples in a tertiary care hospital in Kathmandu, Nepal. Ann Clin Microbiol Antimicrob.2017;16:62.
19.Rai S, Pant ND, Bhandari R, Giri A, Parajuli R, Aryal M, Amatya J, Sharma VK. AmpC and extended spectrum beta-lactamases production among urinary isolates from a tertiary care hospital in Lalitpur, Nepal. BMC Res Notes.2017;10:467.
20.Shrestha S, Amatya R, Dutta R. Prevalence of extended spectrum beta lactamase (ESBL) production in gram negative isolates from pyogenic infection in tertiary care hospital of eastern Nepal. Nepal Med Coll J.2011;13:186–89.
21.Sharma KR, Bhandari P, Adhikari N, Tripathi P, Khanal S, Tiwari BR. Extended Spectrum beta-lactamase (ESBL) Producing Multi Drug Resistant (MDR) Urinary Pathogens in a Children Hospital from Nepal. Kathmandu Univ Med J (KUMJ).2018;16:151–55.
22.Raut S, Adhikari B. ESBL and their identification in peripheral laboratories of Nepal. Nepal Med Coll J. 2015;17:176–81.
23.Parajuli NP, Maharjan P, Parajuli H, Joshi G, Paudel D, Sayami S, Khanal PR. High rates of multidrug resistance among uropathogenic Escherichia coli in children and analyses of ESBL producers from Nepal. Antimicrob Resist Infect Control.2017;6:9.
24.Cheesbrough M. District Laboratory Practice in Tropical Countries. 2nd edition: Cambridge University Press, Cambridge, UK. 2006.
25.Ramadan D, Bassyani E, Amer M, Emam S. Detection of ESBL producing bacteria in cases of UTI in pediatric department of Benha university hospital. Egyptian J Med Microbiol.2016;25:77–84.
26.Forbes BA, Sahm FD, Weissfelt SA. Bailey and Scott;s diagnostic Microbiology. Mosby Publication. 2007.
27.Clinical and Laboratory Standards Institute (CLSI)(2016). Performance standards for antimicrobial susceptibility testing. M100S. Accessed on 20 January, 2017.
28.Shrestha D, Shrestha SP, Gurung K, Manandhar S, Sherchan S. Prevalence of Multidrug resistant Extended Spectrum β-lactamases (ESBL)-producing bacteria from different clinical specimens in Kathmandu Model Hospital, Kathmandu Nepal.EC Microbiol.2016;4: 676–98.
29.Shakya P, Shrestha D, Maharjan E, Sharma VK, Paudyal R. ESBL Production Among E. coli and Klebsiella spp. Causing Urinary Tract Infection: A Hospital Based Study. Open Microbiol J. 2017;11: 23–30.
30.Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev.2005;18:417–22.
31.Desai DJ, Gilbert B, McBride CA. Paediatric urinary tract infections: Diagnosis and treatment. Aust Fam Physician.2016; 45: 558–63.
32.Robinson JL, Finlay JC, Lang ME, Bortolussi R. Urinary tract infections in infants and children: Diagnosis and management.Pediatr Child Health.2014;19: 315–19.
33.Gautam R, Chapagain ML, Acharya A, Rayamajhi N, Shrestha S, Ansari S, Upadhaya G, Nepal HP. Antimicrobial susceptibility patterns of Escherichia coli from various clinical sources. J Chit Med Coll.2013;3: 14–27.
34.Panta K, Ghimire B, Rai S, Mukhiya RK, Singh RN, Rai G. Antibiogram typing of gram-negative isolates in different clinical samples of a tertiary hospital. Asian J Pharm Clin Res.2013;6: 153–56.
35.Lamichhane B. Antibiotic resistance patterns of Gram-negative isolates in a tertiary care hospital of Nepal. Asian J Pharm Clin Res.2014;7: 30–33.
36.Munoz-Davila MJ. Role of Old Antibiotics in the Era of Antibiotic Resistance. Highlighted Nitrofurantoin for the Treatment of Lower Urinary Tract Infections. Antibiotics (Basel). 2014; 3:39–48.
37.Rimal U, Thapa S, Maharajan R. Prevalence of Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella species from urinary specimens of children attending Friendship International Children’s Hospital.Nep J Biotech. 2017;5: 32–38.
38.Ozeki S, Deguchi T, Yasuda M, Nakano M, Kawamura T, Nishino Y, Kawada Y. Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections. J Clin Microbiol.1997; 35:2315–19.
39.Pokharel S, Raut S, Adhikari B. Tackling antimicrobial resistance in low- and middle-income countries. BMJ Glob Health. 2019; 4:e002104.
40.Mishra SK, Awal BK, Kattel HP, Acharya J, Gyawali P, Bhatt CP, Pokhrel BM. Drug resistant bacteria are growing menace in a University Hospital in Nepal. American J Epidem Infec Dis.2014;2: 19–23.
41.Tankhiwale SS, Jalgaonkar SV. Evaluation of extended spectrum beta-lactamases in urinary isolates. Indian J Med Res.2004; 12:1005–1008.
42.Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. Ann Clin Microbiol Antimicrob.2007; 6:4.
43.Hasan AS, Nair D. Resistance patterns of urinary isolates in a tertiary Indian hospital. J Ayub Med College. 2007; 19:39–41.
44.Kulkarni DM, Badrapurkar SA, Nilekar SL, More SR. Prevalence of extended spectrum beta-lactamase producing E. coli and Klebsiella species in urinary isolates. J Dental and Med Sci. 2016; 15:26–29.
45.Sharma AR, Bhatta DR, Shrestha J, Banjara MR. Antimicrobial susceptibility pattern of Escherichia coli isolated from urinary tract infected patients attending Bir Hospital. Nepal J Sci Tech.2013; 14:177–184.
46.Jain A, Roy I, Gupta MK, Kumar M, Agarwal SK. Prevalence of extended-spectrum beta-lactamase-producing Gram-negative bacteria in septicaemic neonates in a tertiary care hospital. J Med Microbiol.2003; 52:421–25.
47.Chander A, Shrestha CD. Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal. BMC Res Notes.2013; 6:487.
48.Brolund A. Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective. Infect Ecol Epidemiol. 2014;4.
49.Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev.2009;22:161–82.
50.Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs.2003;63: 353–65.
51.Ansari S, Nepal HP, Gautam R, Shrestha S, Neopane P, Gurung G, Chapagain ML. Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal. Antimicrob Resist Infect Control.2015;4:15.
52.World Health Organization (WHO). Antimicrobial Resistance: Global Report on Surveillance. 2014. World Health Organization, Geneva.
53.Raut S, Adhikari B. Ceftazidime-avibactam in ceftazidime-resistant infections. Lancet Infect Dis. 2016;16:997.
54.Raut S, Adhikari B. Global leadership against antimicrobial resistance ought to include developing countries. Lancet Infect Dis.2016;16:775.